Autologous formalin-fixed tumour vaccine

Drug Profile

Autologous formalin-fixed tumour vaccine

Alternative Names: AFTV; AFTVac

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell-Medicine
  • Developer Cell-Medicine; University of Tsukuba
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma; Hepatocellular carcinoma

Most Recent Events

  • 03 Feb 2016 Phase-I/II development is ongoing in Japan for Glioblastoma, and Hepatocellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top